SHANDONG XINHUA (00719.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov27

Shandong Newhua Pharmaceutical Obtains Approval for Prednisolone Acetate API

08:33

Shandong Xinhua Pharmaceutical Obtains Approval for Epinephrine Hydrochloride Injection from NMPA

08:32

Nov25

Shandong Xinhua Pharmaceutical Obtains Lidocaine and Procaine Cream Drug Registration Certificate

08:38

Nov17

Xinhua Pharmaceutical's Vonoprazan Receives Marketing Approval from NMPA

08:50

Nov5

Xinhua Pharmaceutical Explains Its Position in Flu Treatment with Analgesics

04:01

Nov4

Xinhua Pharmaceutical's Response Strategies After Winning National Pharmaceutical Bidding

04:02

Schedules & Filings

Schedules

Filings

Oct24

Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 2.322 B, Net Income 35.49 M, EPS 0.0507

Aug26

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 2.418 B, Net Income 122.22 M, EPS 0.1879

Jul18

Distribution Plan(CST)

Cash dividend 0.2731 HKD

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change